Brand new publications published in Q3 using Qube 384 or QPatch

A particularly strong quarter in neglected tropical disease therapeutics was apparent. From foundational work on antibodies neutralising snakebite venom to drug development for malaria, schistosomiasis and cryptosporidiosis were all driven by studies on QPatch.

Our understanding in chronic pain, cancer & respiratory disorders such as asthma & cystic fibrosis was furthered by several academic & industrial labs using Qube & QPatch.

Ledsgaard et al., 2021 In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom. BioRxiv, 2021.09.07.459075.

Hamilton et al., 2021 Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme. Journal of Medicinal Chemistry, 64(15), 11302–11329.

Mambwe et al., 2021 Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against Plasmodium falciparum in Vitro. ACS Medicinal Chemistry Letters, 12(8), 1333–1341

Hao et al., 2021 Emerging Modulators of TMEM16A and Their Therapeutic Potential. Journal of Membrane Biology, 254(4), 353–365

Roecker et al., 2021 Discovery of Arylsulfonamide Nav1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile. ACS Medicinal Chemistry Letters, 12(6), 1038–1049.

Gardner et al., 2021 The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species. PLoS Neglected Tropical Diseases, 15(7), 1–21.

Danziger et al., 2021 Nav1.7 target modulation and efficacy can be measured in nonhuman primate assays. Science Translational Medicine, 13(594), 1–14.

Oboh et al., 2021 Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin. Journal of Medicinal Chemistry, 64(15), 11729–11745.

Shackleford et al., 2021 Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials. Journal of Medicinal Chemistry, 64(17), 12582–12602.

Feng et al., 2021 N -Aromatic-Substituted Indazole Derivatives as Brain-Penetrant and Orally Bioavailable JNK3 Inhibitors. ACS Medicinal Chemistry Letters, 12(10), 1546–1552.